Mendelian Randomization Evidence for Gerotherapeutics

Abstract

Aging-related diseases and functional decline present major public health challenges. Mendelian randomization (MR) offers a robust approach for evaluating gerotherapeutic candidates by leveraging genetic variants as instrumental variables for drug exposures to infer their causal effects on aging outcomes.